Clinical Results of twice-weekly injections for teriparatide

Clinical Results of twice-weekly injections for teriparatide - Clinical Results of twice-weekly injections for teriparatide

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057022

Enrollment

500

Registered

2025-02-19

Start date

2019-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Severe osteoporosis with a history of 1) fractures in two or more locations 2) YAM < 60% 3) a history of one fracture + YAM < 65% 4) vertebral fracture collapse rate > 40%. Patients who can provide written consent regarding this study.

Exclusion criteria

Exclusion criteria: Patients who are contraindicated or require caution when administering teriparatide Malignant tumors Patients who are currently pregnant, breastfeeding, or wish to become pregnant Individuals who are unable to self-inject Individuals who cannot provide consent for research

Design outcomes

Primary

Measure	Time frame
Changes in lumbar and proximal femur bone mineral density, changes in bone metabolism markers, incidence of fractures, and incidence of side effects after 2 years of teriparatide injections twice a week	—

Secondary

Measure	Time frame
Changes in lumbar spine and proximal femur bone mineral density, changes in bone metabolism markers, incidence of fractures, and incidence of side effects in sequential therapy after teriparatide treatment.	—

Countries

Japan

Contacts

Public ContactNiimi Rui

Niimi orthopaedics surgery clinic Orthopaedic surgery

furikakefuri@hotmail.co.jp0594332133

Outcome results